DMAAR
NASDAQ
$0.17
Drugs Made In America Acquisition Corp (DMAAR)
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company targeting the revitalization of domestic pharmaceutical manufacturing to address pressing healthcare needs and supply chain vulnerabilities. Harnessing the expertise of a seasoned management team, DMAAR aims to identify and merge with established pharmaceutical players, positioning itself to leverage growth opportunities in an evolving market. By prioritizing resilience and self-sufficiency in American healthcare, DMAAR offers institutional investors a compelling opportunity for both substantial returns and a positive societal impact within the pharmaceutical sector.
This company is also listed under the following tickers: DMAAU, DMAA.
Website: https://dmaacorp.comMarket Cap
$1.29M
P/E Ratio
0.19
Free Cash Flow Yield
-29.48%
Beta (5Y)
-0.55
Price Chart
Valuation
Market Cap$1.29M
P/E0.19
Profitability
EBITDA$6.66M
EPS$0.63
Financial Health
Free Cash Flow Yield-29.48%
Growth & Risk
Beta (5Y)-0.55
Sharpe Ratio0.29